Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Feb;73(3):301–306. doi: 10.1038/bjc.1996.53

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.

J M Bartlett 1, S P Langdon 1, B J Simpson 1, M Stewart 1, D Katsaros 1, P Sismondi 1, S Love 1, W N Scott 1, A R Williams 1, A M Lessells 1, K G Macleod 1, J F Smyth 1, W R Miller 1
PMCID: PMC2074444  PMID: 8562334

Abstract

The expression of mRNA for the epidermal growth factor (EGF) receptor, EGF and transforming growth factor alpha (TGF-alpha) was determined in 76 malignant, six borderline and 15 benign primary ovarian tumours using the reverse transcriptase-polymerase chain reaction and related to clinical and pathological parameters. Of the malignant tumours, 70% (53/76) expressed EGF receptor mRNA, 31% (23/75) expressed EGF mRNA and 35% (26/75) expressed TGF-alpha mRNA. For the borderline tumours, four of six (67%) expressed EGF receptor mRNA, 1/6 (17%) expressed TGF-alpha mRNA and none expressed EGF mRNA. Finally, 33% (5/15) of the benign tumours expressed EGF receptor mRNA, whereas 40% (6/15) expressed EGF mRNA and 7% (1/15) expressed TGF-alpha mRNA. The presence of the EGF receptor in malignant tumours was associated with that of TGF-alpha (P = 0.0015) but not with EGF (P = 1.00), whereas there was no relationship between the presence of EGF and TGF-alpha (P = 1.00). EGF receptor mRNA expression was significantly and positively associated with serous histology (P = 0.006) but not with stage or grade. Neither EGF nor TGF-alpha showed any link with histological subtype or stage. The survival of patients with malignant tumours possessing EGF receptor mRNA was significantly reduced compared with that of patients whose tumours were negative (P = 0.030 for all malignant tumours; P = 0.007 for malignant epithelial tumours only). In contrast, neither the expression of TGF-alpha nor EGF was related to survival. These data suggest that the presence of EGF receptor mRNA is associated with poor prognosis in primary ovarian cancer.

Full text

PDF
305

Images in this article

303Figure 1
on p.303

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett J. M., Rabiasz G. J., Scott W. N., Langdon S. P., Smyth J. F., Miller W. R. Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells. Br J Cancer. 1992 May;65(5):655–660. doi: 10.1038/bjc.1992.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Battaglia F., Scambia G., Benedetti Panici P., Baiocchi G., Perrone L., Iacobelli S., Mancuso S. Epidermal growth factor receptor expression in gynecological malignancies. Gynecol Obstet Invest. 1989;27(1):42–44. doi: 10.1159/000293614. [DOI] [PubMed] [Google Scholar]
  3. Bauknecht T., Angel P., Kohler M., Kommoss F., Birmelin G., Pfleiderer A., Wagner E. Gene structure and expression analysis of the epidermal growth factor receptor, transforming growth factor-alpha, myc, jun, and metallothionein in human ovarian carcinomas. Classification of malignant phenotypes. Cancer. 1993 Jan 15;71(2):419–429. doi: 10.1002/1097-0142(19930115)71:2<419::aid-cncr2820710224>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  4. Bauknecht T., Birmelin G., Kommoss F. Clinical significance of oncogenes and growth factors in ovarian carcinomas. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):855–862. doi: 10.1016/0960-0760(90)90432-k. [DOI] [PubMed] [Google Scholar]
  5. Bauknecht T., Runge M., Schwall M., Pfleiderer A. Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol. 1988 Feb;29(2):147–157. doi: 10.1016/0090-8258(88)90209-0. [DOI] [PubMed] [Google Scholar]
  6. Berchuck A., Rodriguez G. C., Kamel A., Dodge R. K., Soper J. T., Clarke-Pearson D. L., Bast R. C., Jr Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol. 1991 Feb;164(2):669–674. doi: 10.1016/s0002-9378(11)80044-x. [DOI] [PubMed] [Google Scholar]
  7. Berns E. M., Klijn J. G., Henzen-Logmans S. C., Rodenburg C. J., van der Burg M. E., Foekens J. A. Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. Int J Cancer. 1992 Sep 9;52(2):218–224. doi: 10.1002/ijc.2910520211. [DOI] [PubMed] [Google Scholar]
  8. Cannistra S. A. Cancer of the ovary. N Engl J Med. 1993 Nov 18;329(21):1550–1559. doi: 10.1056/NEJM199311183292108. [DOI] [PubMed] [Google Scholar]
  9. Crew A. J., Langdon S. P., Miller E. P., Miller W. R. Mitogenic effects of epidermal growth factor and transforming growth factor-alpha on EGF-receptor positive human ovarian carcinoma cell lines. Eur J Cancer. 1992;28(2-3):337–341. doi: 10.1016/s0959-8049(05)80049-8. [DOI] [PubMed] [Google Scholar]
  10. Foekens J. A., van Putten W. L., Portengen H., Rodenburg C. J., Reubi J. C., Berns P. M., Henzen-Logmans S. C., van der Burg M. E., Alexieva-Figusch J., Klijn J. G. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):815–821. doi: 10.1016/0960-0760(90)90425-k. [DOI] [PubMed] [Google Scholar]
  11. Henzen-Logmans S. C., Berns E. M., Klijn J. G., van der Burg M. E., Foekens J. A. Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay. Br J Cancer. 1992 Dec;66(6):1015–1021. doi: 10.1038/bjc.1992.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jindal S. K., Snoey D. M., Lobb D. K., Dorrington J. H. Transforming growth factor alpha localization and role in surface epithelium of normal human ovaries and in ovarian carcinoma cells. Gynecol Oncol. 1994 Apr;53(1):17–23. doi: 10.1006/gyno.1994.1080. [DOI] [PubMed] [Google Scholar]
  13. Kohler M., Bauknecht T., Grimm M., Birmelin G., Kommoss F., Wagner E. Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas. Eur J Cancer. 1992;28A(8-9):1432–1437. doi: 10.1016/0959-8049(92)90538-d. [DOI] [PubMed] [Google Scholar]
  14. La Vecchia C., Lucchini F., Negri E., Boyle P., Maisonneuve P., Levi F. Trends of cancer mortality in Europe, 1955-1989: III, Breast and genital sites. Eur J Cancer. 1992;28A(4-5):927–998. doi: 10.1016/0959-8049(92)90153-s. [DOI] [PubMed] [Google Scholar]
  15. Morishige K., Kurachi H., Amemiya K., Fujita Y., Yamamoto T., Miyake A., Tanizawa O. Evidence for the involvement of transforming growth factor alpha and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res. 1991 Oct 1;51(19):5322–5328. [PubMed] [Google Scholar]
  16. Owens O. J., Stewart C., Brown I., Leake R. E. Epidermal growth factor receptors (EGFR) in human ovarian cancer. Br J Cancer. 1991 Nov;64(5):907–910. doi: 10.1038/bjc.1991.424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Owens O. J., Stewart C., Leake R. E. Growth factors in ovarian cancer. Br J Cancer. 1991 Dec;64(6):1177–1181. doi: 10.1038/bjc.1991.486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Owens O. J., Stewart C., Leake R. E., McNicol A. M. A comparison of biochemical and immunohistochemical assessment of EGFR expression in ovarian cancer. Anticancer Res. 1992 Sep-Oct;12(5):1455–1458. [PubMed] [Google Scholar]
  19. Rodriguez G. C., Berchuck A., Whitaker R. S., Schlossman D., Clarke-Pearson D. L., Bast R. C., Jr Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol. 1991 Mar;164(3):745–750. doi: 10.1016/0002-9378(91)90508-o. [DOI] [PubMed] [Google Scholar]
  20. Scambia G., Benedetti Panici P., Battaglia F., Ferrandina G., Baiocchi G., Greggi S., De Vincenzo R., Mancuso S. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol. 1992 Apr;10(4):529–535. doi: 10.1200/JCO.1992.10.4.529. [DOI] [PubMed] [Google Scholar]
  21. Scambia G., Ranelletti F. O., Benedetti Panici P., Piantelli M., Bonanno G., De Vincenzo R., Ferrandina G., Pierelli L., Capelli A., Mancuso S. Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites. Cancer Chemother Pharmacol. 1991;28(4):255–258. doi: 10.1007/BF00685531. [DOI] [PubMed] [Google Scholar]
  22. Zhou L., Leung B. S. Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors alpha and beta 1. Biochim Biophys Acta. 1992 Dec 10;1180(2):130–136. doi: 10.1016/0925-4439(92)90061-q. [DOI] [PubMed] [Google Scholar]
  23. van der Burg M. E., Henzen-Logmans S. C., Foekens J. A., Berns E. M., Rodenburg C. J., van Putten W. L., Klijn J. G. The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur J Cancer. 1993;29A(14):1951–1957. doi: 10.1016/0959-8049(93)90451-k. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES